Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: J Neurooncol. 2020 Mar 17;147(2):281–295. doi: 10.1007/s11060-020-03450-7

Figure 2: T-cell based immunotherapy modalities:

Figure 2:

Ongoing T-cell based cancer immunotherapy studies encompass both vaccine therapy and adoptive cell transfer (ACT). Vaccines (upper-left) focus on eliciting a cytotoxic immune response by introducing tumor-associated or tumor-specific antigens for APC presentation. Tumor-infiltrating lymphocyte (TIL) therapy (upper-right) selects for and expands tumor-specific lymphocytes ex vivo for reinfusion into the patient. TCR and chimeric-antigen receptor (CAR) T-cell therapy (bottom) incorporates the design and incorporation of an antigen-specific receptor into a T-cell.